|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Normanno N, Bianco C, De Luca A and
Salomon DS: The role of EGF-related peptides in tumor growth. Front
Biosci. 6:D685–D707. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Maemondo M, Inoue A, Kobayashi K, et al:
Gefitinib or chemotherapy for non-small-cell lung cancer with
mutated EGFR. N Engl J Med. 362:2380–2388. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rosell R, Carcereny E, Gervais R, et al:
Spanish Lung Cancer Group in collaboration with Groupe Français de
Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica:
Erlotinib versus standard chemotherapy as first-line treatment for
European patients with advanced EGFR mutation-positive
non-small-cell lung cancer (EURTAC): A multicentre, open-label,
randomised phase 3 trial. Lancet Oncol. 13:239–246. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Nguyen KS, Kobayashi S and Costa DB:
Acquired resistance to epidermal growth factor receptor tyrosine
kinase inhibitors in non-small-cell lung cancers dependent on the
epidermal growth factor receptor pathway. Clin Lung Cancer.
10:281–289. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Pao W, Miller VA, Politi KA, Riely GJ,
Somwar R, Zakowski MF, Kris MG and Varmus H: Acquired resistance of
lung adenocarcinomas to gefitinib or erlotinib is associated with a
second mutation in the EGFR kinase domain. PLoS Med. 2:e732005.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Thomson S, Buck E, Petti F, Griffin G,
Brown E, Ramnarine N, Iwata KK, Gibson N and Haley JD: Epithelial
to mesenchymal transition is a determinant of sensitivity of
non-small-cell lung carcinoma cell lines and xenografts to
epidermal growth factor receptor inhibition. Cancer Res.
65:9455–9462. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Suda K, Tomizawa K, Fujii M, Murakami H,
Osada H, Maehara Y, Yatabe Y, Sekido Y and Mitsudomi T: Epithelial
to mesenchymal transition in an epidermal growth factor
receptor-mutant lung cancer cell line with acquired resistance to
erlotinib. J Thorac Oncol. 6:1152–1161. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Onitsuka T, Uramoto H, Nose N, Takenoyama
M, Hanagiri T, Sugio K and Yasumoto K: Acquired resistance to
gefitinib: The contribution of mechanisms other than the T790M,
MET, and HGF status. Lung Cancer. 68:198–203. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Shintani Y, Maeda M, Chaika N, Johnson KR
and Wheelock MJ: Collagen I promotes epithelial-to-mesenchymal
transition in lung cancer cells via transforming growth factor-beta
signaling. Am J Respir Cell Mol Biol. 38:95–104. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Damiano JS, Cress AE, Hazlehurst LA, Shtil
AA and Dalton WS: Cell adhesion mediated drug resistance (CAM-DR):
Role of integrins and resistance to apoptosis in human myeloma cell
lines. Blood. 93:1658–1667. 1999.PubMed/NCBI
|
|
12
|
Giancotti FG and Ruoslahti E: Integrin
signaling. Science. 285:1028–1032. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hynes RO: Integrins: Bidirectional,
allosteric signaling machines. Cell. 110:673–687. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
White DE, Kurpios NA, Zuo D, Hassell JA,
Blaess S, Mueller U and Muller WJ: Targeted-integrin in a
transgenic mouse model disruption of human breast cancer reveals an
essential role in mammary tumor induction. Cancer Cell. 6:159–170.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zutter MM, Santoro SA, Staatz WD and Tsung
YL: Re-expression of the alpha 2 beta 1 integrin abrogates the
malignant phenotype of breast carcinoma cells. Proc Natl Acad Sci
USA. 92:7411–7415. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Emmons MF, Gebhard AW, Nair RR, Baz R,
McLaughlin ML, Cress AE and Hazlehurst LA: Acquisition of
resistance toward HYD1 correlates with a reduction in cleaved α4
integrin expression and a compromised CAM-DR phenotype. Mol Cancer
Ther. 10:2257–2266. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Martin S, Janouskova H and Dontenwill M:
Integrins and p53 pathways in glioblastoma resistance to
temozolomide. Front Oncol. 2:1572012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Scalici JM, Harrer C, Allen A, Jazaeri A,
Atkins KA, McLachlan KR and Slack-Davis JK: Inhibition of α4β1
integrin increases ovarian cancer response to carboplatin. Gynecol
Oncol. 132:455–461. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hodkinson PS, Mackinnon AC and Sethi T:
Extracellular matrix regulation of drug resistance in small-cell
lung cancer. Int J Radiat Biol. 83:733–741. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Velling T, Stefansson A and Johansson S:
EGFR and beta1 integrins utilize different signaling pathways to
activate Akt. Exp Cell Res. 314:309–316. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Koizumi F, Shimoyama T, Taguchi F, Saijo N
and Nishio K: Establishment of a human non-small cell lung cancer
cell lines resistant to gefitinib. Int J Cancer. 116:36–44. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bradford MM: A rapid and sensitive method
for the quantitation of microgram quantities of protein utilizing
the principle of protein-dye binding. Anal Biochem. 72:248–254.
1976. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Laskin JJ and Sandler AB: Epidermal growth
factor receptor: A promising target in solid tumors. Cancer Treat
Rev. 30:1–17. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhou C, Wu YL, Chen G, Feng J, Liu XQ,
Wang C, Zhang S, Wang J, Zhou S, Ren S, et al: Erlotinib versus
chemotherapy as first-line treatment for patients with advanced
EGFR mutation-positive non-small-cell lung cancer (OPTIMAL,
CTONG-0802): A multicentre, open-label, randomised, phase 3 study.
Lancet Oncol. 12:735–742. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Fukuoka M, Yano S, Giaccone G, Tamura T,
Nakagawa K, Douillard JY, Nishiwaki Y, Vansteenkiste J, Kudoh S,
Rischin D, et al: Multi-institutional randomized phase II trial of
gefitinib for previously treated patients with advanced
non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin
Oncol. 21:2237–2246. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Thatcher N, Chang A, Parikh P, Rodrigues
Pereira J, Ciuleanu T, von Pawel J, Thongprasert S, Tan EH,
Pemberton K, Archer V and Carroll K: Gefitinib plus best supportive
care in previously treated patients with refractory advanced
non-small-cell lung cancer: Results from a randomized,
placebo-controlled, multicentre study (Iressa Survival Evaluation
in Lung Cancer). Lancet. 366:1527–1537. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Shepherd FA, Rodrigues Pereira J, Ciuleanu
T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S,
Smylie M, Martins R, et al: National Cancer Institute of Canada
Clinical Trials Group: Erlotinib in previously treated
non-small-cell lung cancer. N Engl J Med. 353:123–132. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Parise LV, Lee J and Juliano RL: New
aspects of integrin signaling in cancer. Semin Cancer Biol.
10:407–414. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Aoudjit F and Vuori K: Integrin signaling
inhibits paclitaxel-induced apoptosis in breast cancer cells.
Oncogene. 20:4995–5004. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Plopper GE, McNamee HP, Dike LE,
Bojanowski K and Ingber DE: Convergence of integrin and growth
factor receptor signaling pathways within the focal adhesion
complex. Mol Biol Cell. 6:1349–1365. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lee HY, Srinivas H, Xia D, Lu Y, Superty
R, LaPushin R, Gomez-Manzano C, Gal AM, Walsh GL, Force T, et al:
Evidence that phosphadidylinositol 3-kinase- and mitogen-activated
protein kinase kinase-4/c-Jun NH2-terminal kinase-dependent
pathways cooperate to maintain lung cancer cell survival. J Biol
Chem. 278:23630–23638. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zeller KS, Idevall-Hagren O, Stefansson A,
Velling T, Jackson SP, Downward J, Tengholm A and Johansson S:
PI3-kinase p110α mediates β1 integrin-induced Akt activation and
membrane protrusion during cell attachment and initial spreading.
Cell Signal. 22:1838–1848. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Gilmore AP, Metcalfe AD, Romer LH and
Streuli CH: Integrin-mediated survival signals regulate the
apoptotic function of bax through conformation and subcellular
localization. J Cell Biol. 149:431–446. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Sethi T, Rintoul RC, Moore SM, MacKinnon
AC, Salter D, Choo C, Chilvers ER, Dransfield I, Donnelly SC,
Strieter R and Haslett C: Extracellular matrix proteins protect
small cell lung cancer cells against apoptosis: A mechanism for
small cell lung cancer growth and drug resistance in vivo. Nat Med.
5:662–668. 1999. View
Article : Google Scholar : PubMed/NCBI
|
|
35
|
Cabodi S, Morello V, Masi A, Cicchi R,
Broggio C, Distefano P, Brunelli E, Silengo L, Pavone F, Arcangeli
A, et al: Convergence of integrins and EGF receptor signaling via
PI3K/Akt/FoxO pathway in early gene Egr-1 expression. J Cell
Physiol. 218:294–303. 2009. View Article : Google Scholar : PubMed/NCBI
|
